Anticancer therapy: Boosting the bang of Bim

Research output: Contribution to journalComment/debatepeer-review

14 Scopus citations


Even though activating mutations of B-Raf, a kinase atop the MAPK signaling cascade, reportedly sensitize tumor cells to MEK inhibitors, Raf and MEK inhibitors have exhibited limited clinical activity. In this issue of the JCI, Cragg et al. report that MEK inhibition upregulates the proapoptotic Bcl-2 family member Bim but induces little regression of human melanoma xenografts in mice unless the Bcl-2 antagonist ABT-737 is added (see the related article, doi:10.1172/JCI35437). These findings illustrate the potential benefit of simultaneously inhibiting oncogenic kinases and inhibiting Bcl-2 action in solid tumors.

Original languageEnglish (US)
Pages (from-to)3582-3584
Number of pages3
JournalJournal of Clinical Investigation
Issue number11
StatePublished - Nov 3 2008

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Anticancer therapy: Boosting the bang of Bim'. Together they form a unique fingerprint.

Cite this